The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study

Olfatifar, Meysam; Zali, Mohammad Reza; Pourhoseingholi, Mohamad Amin; Balaii, Hedieh; Ghavami, Shaghayegh Baradaran; Іванчук, М. А.; Іванчук, П. Р.; Hashemi-Nazari, Seyed Saeed; Shahrokh, Shabnam; Sabour, Siamak; Khodakarim, Soheila; Aghdaei, Hamid Asadzadeh; Rohani, Pejman; Mehralian, Gholamhossein

doi:10.1186/s12876-021-01745-1

Cited by 37 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the huge population in Asian countries, including China and India, Asia alone might have a greater disease burden with IBD than that of the Western world in the near future. One modeling study from Iran expected a 1.5-fold increase in prevalence for East Asia with 4.5 million cases of IBD and quadrupling of the prevalence for India with 2.2 million cases of IBD in 2035, as compared to 2020 [ 38 ]. However, data should be interpreted with caution given the vast heterogeneity between the reported incidence rates among the Asian countries and regions within these countries, such as data of the ACCESS [ 4 , 30 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?

Park

2022

Intest Res

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) has become a global disease. As IBD is a chronic disease that can result in remarkable morbidity and disability, estimation and understanding the disease burden of IBD is imperative to prepare adequate health care systems. However, variations in IBD incidence or prevalence may reflect differences in the distribution, and there are regional disparities in Asia with a large population of approximately 4.6 billion in 2020, which is equivalent to 60% of the total world population. Although comprehensive understanding of the epidemiology of IBD in Asian countries is difficult, this review includes updated data regarding the incidence and prevalence of IBD and the estimated disease burden in Asia.

show abstract

Section: Discussionmentioning

confidence: 99%

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?

Park

2022

Intest Res

View full text Add to dashboard Cite

show abstract

“…The prevalence rates of IBD have a different geographic distribution, with high rates in Europe and North America and low rates in Asia [ 2 ]. It is important that an increase in the incidence of IBD and a decrease in the onset age up to childhood are observed [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Boldyreva

Морозова

Saydakova³

et al. 2021

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) comprise a distinct set of clinical symptoms resulting from chronic inflammation within the gastrointestinal (GI) tract. Despite the significant progress in understanding the etiology and development of treatment strategies, IBD remain incurable for thousands of patients. Metabolic deregulation is indicative of IBD, including substantial shifts in lipid metabolism. Recent data showed that changes in some phospholipids are very common in IBD patients. For instance, phosphatidylcholine (PC)/phosphatidylethanolamine (PE) and lysophosphatidylcholine (LPC)/PC ratios are associated with the severity of the inflammatory process. Composition of phospholipids also changes upon IBD towards an increase in arachidonic acid and a decrease in linoleic and a-linolenic acid levels. Moreover, an increase in certain phospholipid metabolites, such as lysophosphatidylcholine, sphingosine-1-phosphate and ceramide, can result in enhanced intestinal inflammation, malignancy, apoptosis or necroptosis. Because some phospholipids are associated with pathogenesis of IBD, they may provide a basis for new strategies to treat IBD. Current attempts are aimed at controlling phospholipid and fatty acid levels through the diet or via pharmacological manipulation of lipid metabolism.

show abstract

“…The prevalence of IBD in North Africa and the Middle East is expected to increase by 2.3-fold between 2020 to 2035. 4 The prevalence of depression is higher among patients with chronic diseases than in the general population. Therefore, having a long-term medical illness is a risk factor for depression.…”

Section: Introductionmentioning

confidence: 99%

Clinical Predictors of Depression among Patients with Inflammatory Bowel Diseases: A Cross-sectional Analytical Study from Oman

AL-Amri¹,

Al‐Huseini²,

Chan³

et al. 2022

Oman Med J

View full text Add to dashboard Cite

Objectives: Many studies suggest that depression is prevalent among patients suffering from inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Notably, both depression and IBD have a significant disease burden. However, these studies have mostly been conducted among European and American populations; there is a paucity of these studies from Arabic countries. This study aimed to examine the prevalence and predictors of depressive symptoms among adult IBD patients attending a tertiary care hospital in Muscat, Oman. Methods: This was a cross-sectional study, conducted among a random sample of patient's aged18 years and older who attended the gastroenterology clinic at Sultan Qaboos University Hospital, Muscat, Oman between June 2018, and January 2019. Participants were asked to complete the Patient Health Questionnaire-9 (PHQ-9) to assess depression, as well as a sociodemographic survey. Logistic regression analysis was used to identify the independent predictors of depressive symptoms among the study sample. Adjusted odds ratios (OR) were also reported. Results: This study included 201participants, within average age of 36years. Of this study, 51% were female. The mean duration of the patients’IBD diagnosis was 1.9 years (standard deviation=0.3), the majority of the participants (87%) had ulcerative colitis (n=174), 80% of the participants had received steroids (n=161), and 6% of the sample had a history of a surgical stoma. The medical comorbidities among the participants were cerebrovascular accidents (25%), hypertension (25%) and diabetes mellitus (24%). The prevalence of depressive symptoms was 23%. The logistic regression analysis resulted in four independent predictors of depression: being female (odds ratio [OR] =2.09, P=0.047), a history of surgical stoma (OR=5.737, P<.001), a comorbid diagnosis of hypertension (OR=2.846, P=0.007), and a history of a cerebrovascular accident (OR=2.651, P=0.011). Conclusion: The present study found that depressive symptoms are prevalent among Omani patients with IBD. Certain clinical factors appeared to increase the risk of depression among this population. The findings of this study fill a gap in the existing literature and call for further work aiming at screening and managing depression among IBD patients.

show abstract

The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study

Cited by 37 publications

References 27 publications

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Clinical Predictors of Depression among Patients with Inflammatory Bowel Diseases: A Cross-sectional Analytical Study from Oman

Contact Info

Product

Resources

About